A Phase III, Randomized, Multi-center Clinical Trial That Will Examine Whether Treatment With Intravenous TNK is Superior to Placebo in Patients Who Suffer a Non-large Vessel Occlusion Ischemic Stroke Within 4.5-12 Hours From Time Last Seen Well

Who is this study for? Patients with Stroke
What treatments are being studied? Intravenous Tenecteplase
Status: Recruiting
Location: See all (15) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

A phase III, randomized, multi-center clinical trial that will examine whether treatment with intravenous TNK is superior to placebo in patients who suffer a non-large vessel occlusion ischemic stroke within 4.5-12 hours from time last seen well. The randomization employs a 1:1 ratio of intravenous thrombolysis with Tenecteplase (TNK) versus placebo in patients who suffer a non-large vessel occlusion ischemic stroke between 4.5 and 12 hours from time last seen well (TLSW) and with a clinical-radiological mismatch or evidence of salvageable brain tissue on perfusion imaging.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Acute ischemic stroke where patient is ineligible for IV thrombolytic treatment with Alteplase due to onset \>4.5 hours and is ineligible for endovascular treatment under standard of care due to absence of proximal arterial occlusion (e.g. intracranial ICA, MCA-M1 and dominant M2 segments, and vertebrobasilar arteries).

• \* Dominant M2 segment is defined is a division supplying \>50% of the MCA territory vs co-dominant supplying 50% of the MCA territory vs non-dominant supplying \<50% of the MCA territory.

• No significant pre-stroke functional disability (mRS ≤2).

• Age ≥18 years (no upper age limit).

• Clinical or imaging mismatch evidence in distal artery territories, defined as one of the following scenarios (A, B or C):

‣ Scenario A - all of the following:

• Significant cortical neurological deficit (moderate to severe afasia, moderate to severe heminegligence, severe hemianopsia) with the addition or not of motor symptoms OR any motor deficit accompanied of cortical symptoms of any severity;

∙ Contrast-enhanced CT of the head or head MRI with \<50% involvement of the vascular territory corresponding to the clinical manifestation;

∙ Arterial head angiotomography or arterial head angioMRI WITHOUT proximal intracranial artery occlusion that would require endovascular therapy (for example, ICA intracranial, MCA-M1 and M2 dominant segments and vertebral and basilar arteries)

⁃ Scenario B - all of the following:

• NIHSS score ≥ 4 due to any neurologic deficits;

∙ Non-contrast CT of the head or head MRI com \<50% involvement of the vascular territory corresponding to the clinical manifestation;

∙ Arterial head angioCT or arterial head MRI WITHOUT proximal intracranial artery occlusion that would require endovascular therapy (for example, ICA intracranial, MCA-M1 and M2 dominant segments and vertebral and basilar arteries)

∙ Arterial head angioCT with distal occlusion on MIP or wedge-shaped lesion on parenchymography on the source-image of angiotomography OR CT perfusion with wedge-shaped cortical lesion.

⁃ Scenario C - all of the following:

• NIHSS score ≥ 4 due to any neurologic deficits;

∙ The presence of a Target Mismatch defined as:

‣ Ischemic Core \<50cc (defined on NCCT/CTP\* or DWI MRI) \*Volume NCCT can be used to exclude patients if the investigator believes that its volume assessment is more reliable that the CTP in any particular case.

⁃ Mismatch Volume (Tmax \>6sec lesion - Core volume lesion) \>10cc

⁃ Mismatch Ratio \>1.4

• Patient treatable within 4.5-12 hours of symptom onset. Symptoms onset is defined as point in time the patient was last seen well (at baseline). Treatment start is defined as initiation of IV TNK or placebo infusion.

‣ Patients who have woken up with the symptoms and don't have a mismatch FLAIR-DWI according to the WAKE-UP Trial image criteria will have their window considered to be \>4.5 hours. In this case, the time last seen well must have been 12 hours at most.

• Informed consent obtained from patient or acceptable patient surrogate.

Locations
Other Locations
Brazil
Hospital das Clínicas Botucatu
RECRUITING
Botucatu
Hospital das Clínicas - UNICAMP
RECRUITING
Campinas
Hospital Universitário Maria Aparecida Pedrossian
RECRUITING
Campo Grande
Hospital das Clínicas UFPR
RECRUITING
Curitiba
Hospital Geral de Fortaleza
RECRUITING
Fortaleza
Clinica Neurologica e Neurocirurgica de Joinville
RECRUITING
Joinville
Hospital Metropolitano de Maceió
RECRUITING
Maceió
Hospital de Clínicas de Porto Alegre
RECRUITING
Porto Alegre
Hospital de Clínicas de Porto Alegre
RECRUITING
Porto Alegre
Hospital Moinhos de Vento
RECRUITING
Porto Alegre
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - Universidade de São Paulo
RECRUITING
Ribeirão Preto
Hospital de Base São José do Rio Preto
RECRUITING
São José Do Rio Preto
Hospital São Paulo
RECRUITING
São Paulo
Santa Casa de Misericordia de Sao Paulo
RECRUITING
São Paulo
Hospital Estadual Central
RECRUITING
Vitória
Contact Information
Primary
Gisele Sampaio Silva, MD, MPH, PhD
giselesampaio@hotmail.com
5511983580583
Backup
Leonardo Carbonera, MD, MsC
leonardo.carbonera@hmv.org.br
555135378195
Time Frame
Start Date: 2022-01-20
Estimated Completion Date: 2027-07
Participants
Target number of participants: 466
Treatments
Placebo_comparator: Control group
Placebo administered as a single bolus injection over 5 seconds
Experimental: Intravenous tenecteplase (TNK)
Intravenous thrombolysis with Tenecteplase (TNK) at a dose of 0.25 mg/Kg (maximum 25mg, administered as a bolus over 5 seconds)
Related Therapeutic Areas
Sponsors
Collaborators: Boehringer Ingelheim, Ministry of Health, Brazil, iSchemaView, Inc, Brainomix Limited
Leads: Hospital Moinhos de Vento

This content was sourced from clinicaltrials.gov

Similar Clinical Trials